Omega Therapeutics, Inc. (OMGA)

NASDAQ: OMGA · IEX Real-Time Price · USD
6.71
+0.01 (0.15%)
Nov 29, 2022 4:00 PM EDT - Market closed
0.15%
Market Cap 321.93M
Revenue (ttm) 144,000
Net Income (ttm) -92.73M
Shares Out 47.85M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,108
Open 6.77
Previous Close 6.7
Day's Range 6.42 - 6.94
52-Week Range 1.98 - 18.61
Beta n/a
Analysts Buy
Price Target 15.91 (+137.1%)
Earnings Date Nov 9, 2022

About OMGA

Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. Its OMEGA Epigenomic Programming platform harnesses the power of epigenetics, as well as the mechanism that controls gene expression and aspect of an organism's life. The company's platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a range without altering native nucleic acid sequences. Its modular and programmable mRNA medicines, and Omega Epigenomic Controllers are designed to tar... [Read more]

Industry Biotechnology
IPO Date Jul 30, 2021
Employees 79
Stock Exchange NASDAQ
Ticker Symbol OMGA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for OMGA stock is "Buy." The 12-month stock price forecast is 15.91, which is an increase of 137.11% from the latest price.

Price Target
$15.91
(137.11% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Wall Street Analysts Think Omega Therapeutics, Inc. (OMGA) Could Surge 136%: Read This Before Placing a Bet

The mean of analysts' price targets for Omega Therapeutics, Inc. (OMGA) points to a 135.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen...

1 day ago - Zacks Investment Research

Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass. , Nov. 17, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeuti...

1 week ago - PRNewsWire

Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

CAMBRIDGE, Mass. , Nov. 15, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeuti...

2 weeks ago - PRNewsWire

Wall Street Analysts Believe Omega Therapeutics, Inc. (OMGA) Could Rally 229%: Here's is How to Trade

The consensus price target hints at a 229.3% upside potential for Omega Therapeutics, Inc. (OMGA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea...

2 weeks ago - Zacks Investment Research

Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

First Patient Dosed in Phase 1/2 MYCHELANGELO™  I Trial of OTX-2002 OTX-2002 Granted Orphan Drug Designation by U.S. FDA for the Treatment of Hepatocellular Carcinoma OTX-2101 for MYC-Driven Non-Small C...

3 weeks ago - PRNewsWire

Omega Therapeutics to Participate in the Jefferies London Healthcare Conference

CAMBRIDGE, Mass. , Nov. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutic...

3 weeks ago - PRNewsWire

Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

Phase 1/2 MYCHELANGELO™ I Clinical Trial Underway to Evaluate Safety, Tolerability and Preliminary Antitumor Activity of OTX-2002 CAMBRIDGE, Mass. , Nov. 2, 2022 /PRNewswire/ -- Omega Therapeutics, Inc....

3 weeks ago - PRNewsWire

Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carc...

OTX-2002 is the First-Ever Epigenomic Controller in a New Class of Programmable mRNA Therapeutics to be Administered to Patients CAMBRIDGE, Mass. , Oct. 27, 2022 /PRNewswire/ -- Omega Therapeutics, Inc....

1 month ago - PRNewsWire

Omega Therapeutics Unveils New Epigenomic Controller Development Candidate Targeting MYC-Driven Non-Small Cell Lung C...

OTX-2101 is the Second Development Candidate Arising from the Company's Pioneering OMEGA Epigenomic Programming™ Platform CAMBRIDGE, Mass. , Oct. 12, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasda...

1 month ago - PRNewsWire

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass. , Sept. 26, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeut...

2 months ago - PRNewsWire

Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

CAMBRIDGE, Mass. , Sept. 6, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeuti...

2 months ago - PRNewsWire

Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

Former Novartis Veteran Brings Deep Expertise in Drug Development and Commercialization CAMBRIDGE, Mass. , Sept. 1, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-sta...

Other symbols: CLLSHGEN
2 months ago - PRNewsWire

Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

FDA Clearance of IND Application for OTX-2002, the First Ever Epigenomic Controller,  for MYC Driven Hepatocellular Carcinoma Received Launch of Phase 1/2 Clinical Trial Under the MYCHELANGELOTM  Clinic...

3 months ago - PRNewsWire

Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

CAMBRIDGE, Mass. , Aug. 3, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutic...

3 months ago - PRNewsWire

Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MY...

Represents First Ever Epigenomic Controller, a New Class of Programmable mRNA Therapeutics, to Receive IND Clearance Phase 1/2 Clinical Trial Expected to Launch in 2H'22 and Will Evaluate the Safety and...

4 months ago - PRNewsWire

Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential...

Treatment with epigenomic controller, OTX-2002, resulted in robust in vivo efficacy in xenograft tumor models OTX-2002 successfully achieved pre-transcriptional downregulation of hepatocyte MYC gene exp...

4 months ago - PRNewsWire

Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular ...

CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therape...

5 months ago - PRNewsWire

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Con...

Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics CAMBRIDGE, Mass. , June 15, 2022 /PRNewswire/ -- Omega...

5 months ago - PRNewsWire

Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthc...

CAMBRIDGE, Mass. , June 2, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeu...

5 months ago - PRNewsWire

Omega Therapeutics, Inc. (OMGA) Upgraded to Buy: What Does It Mean for the Stock?

Omega Therapeutics, Inc. (OMGA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

6 months ago - Zacks Investment Research

Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Investigational New Drug Application for OTX-2002 for MYC Driven Hepatocellular Carcinoma on Track to be Submitted in the First Half of 2022 Additional Omega Epigenomic Controller™ Development Candidate...

6 months ago - PRNewsWire

Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promi...

Regulation of MYC gene expression via epigenomic programming results in decreased viability of cancer cells in vitro and reduced tumor burden in in vivo xenograft models Data demonstrate potential of Om...

6 months ago - PRNewsWire

Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer

Roger Sawhney, M.D. to serve as Chief Business Officer CAMBRIDGE, Mass.

7 months ago - PRNewsWire

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatmen...

OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell viability in vitro and reduces tumor growth in in vivo xenograft models Data support the potential of the OMEGA Epigenomic Pr...

7 months ago - PRNewsWire

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth

Kevin McManus Appointed as Chief Human Resources Officer Ling Zeng, Esq., Appointed as Chief Legal and Administrative Officer CAMBRIDGE, Mass.

7 months ago - PRNewsWire